Parnax Lab [PARNAXLAB] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Parnax Lab
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Parnax Lab wins in 11 metrics, Aarti Drugs wins in 8 metrics, with 0 ties. Parnax Lab appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Parnax Lab | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.99 | 23.41 | Parnax Lab |
| Price-to-Book Ratio | 1.69 | 3.22 | Parnax Lab |
| Debt-to-Equity Ratio | 83.52 | 44.92 | Aarti Drugs |
| PEG Ratio | -0.73 | 0.37 | Parnax Lab |
| EV/EBITDA | 8.04 | 16.91 | Parnax Lab |
| Profit Margin (TTM) | 5.67% | 7.80% | Aarti Drugs |
| Operating Margin (TTM) | 10.29% | 10.11% | Parnax Lab |
| EBITDA Margin (TTM) | 10.29% | 10.11% | Parnax Lab |
| Return on Equity | 13.84% | 12.28% | Parnax Lab |
| Return on Assets (TTM) | 6.07% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $137.24M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 10.65% | -19.35% | Parnax Lab |
| Price-to-Sales Ratio (TTM) | 0.74 | 1.82 | Parnax Lab |
| Enterprise Value | $2.07B | $50.02B | Aarti Drugs |
| EV/Revenue Ratio | 1.09 | 2.07 | Parnax Lab |
| Gross Profit Margin (TTM) | 43.83% | 36.77% | Parnax Lab |
| Revenue per Share (TTM) | $166 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $9.43 | $20.63 | Aarti Drugs |
| Beta (Stock Volatility) | 0.46 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Parnax Lab vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Parnax Lab | 4.48% | 6.15% | 9.38% | 43.81% | 42.55% | -21.14% |
| Aarti Drugs | -2.26% | -4.22% | -10.91% | 0.60% | 27.06% | 3.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Parnax Lab | 10.65% | 44.25% | 647.19% | 397.20% | 828.12% | 1,483.33% |
| Aarti Drugs | -19.35% | 7.87% | -34.19% | 253.95% | 2,524.51% | 2,343.09% |
Performance & Financial Health Analysis: Parnax Lab vs Aarti Drugs
| Metric | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.41B | ₹44.09B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,491 | 143,069 |
| 90 Day Avg. Volume | 6,550 | 595,539 |
| Last Close | ₹133.00 | ₹470.05 |
| 52 Week Range | ₹81.00 - ₹193.50 | ₹312.00 - ₹635.00 |
| % from 52W High | -31.27% | -25.98% |
| All-Time High | ₹193.50 (Nov 04, 2024) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -31.27% | -54.23% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.06% |
| Quarterly Earnings Growth | -0.18% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.08% |
| Operating Margin (TTM) | 0.10% | 0.10% |
| Return on Equity (TTM) | 0.14% | 0.12% |
| Debt to Equity (MRQ) | 83.52 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹72.57 | ₹149.84 |
| Cash per Share (MRQ) | ₹2.34 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹297.41M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹115.19M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Parnax Lab vs Aarti Drugs
| Metric | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.99 | 23.41 |
| Forward P/E | N/A | 14.95 |
| PEG Ratio | -0.73 | 0.37 |
| Price to Sales (TTM) | 0.74 | 1.82 |
| Price to Book (MRQ) | 1.69 | 3.22 |
| Market Capitalization | ||
| Market Capitalization | ₹1.41B | ₹44.09B |
| Enterprise Value | ₹2.07B | ₹50.02B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.09 | 2.07 |
| Enterprise to EBITDA | 8.04 | 16.91 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.21 |
| Book Value per Share (MRQ) | ₹72.57 | ₹149.84 |
Financial Statements Comparison: Parnax Lab vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹533.76M | ₹6.77B |
| Cost of Goods Sold | ₹299.82M | ₹4.37B |
| Gross Profit | ₹233.94M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹54.94M | ₹784.50M |
| EBITDA | ₹76.21M | ₹951.90M |
| Pre-Tax Income | ₹44.55M | ₹711.50M |
| Income Tax | ₹11.80M | ₹83.80M |
| Net Income (Profit) | ₹32.75M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹5.50M | ₹45.80M |
| Total Current Assets | ₹683.40M | ₹13.38B |
| Total Current Liabilities | ₹743.34M | ₹8.37B |
| Long-Term Debt | ₹262.42M | ₹2.86B |
| Total Shareholders Equity | ₹832.42M | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹1.09B | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,491 | 143,069 |
| Average Daily Volume (90 Day) | 6,550 | 595,539 |
| Shares Outstanding | 11.49M | 91.27M |
| Float Shares | 2.99M | 35.46M |
| % Held by Insiders | 0.74% | 0.60% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Parnax Lab vs Aarti Drugs
| Metric | PARNAXLAB | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | N/A | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |